Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Next Previous
X
Search
Trial Profile

A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APR003 (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Adverse reactions
  • Sponsors Apros Therapeutics

    • Most Recent Events

    • 31 Jan 2023 Status changed from recruiting to completed.
    • 07 Nov 2022 Interim results presented in an Apros Therapeutics Media Release.
    • 07 Nov 2022 According to an Apros Therapeutics media release, interim pharmacokinetic and pharmacodynamic data will be presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting and World Vaccine & Immunotherapy Congress 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top